Phase II
ASLAN Pharmaceuticals announced late-breaking topline data from a phase 2 study conducted in China testing varlitinib and capecitabine in second line BTC patients.
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Acceleron Pharma said the Phase II FSHD trial assessing the efficacy of ACE-083 did not achieve functional secondary endpoints during the study.
Days after the Cambridge-based company halted its BACE inhibitor program for Alzheimer’s disease, the company stopped another clinical trial in idiopathic pulmonary fibrosis due to safety reasons.
NOXXON Pharma N.V. announced the start of recruitment of newly diagnosed brain cancer patients in a Phase 1/2 clinical trial combining the CXCL12 inhibitor NOX-A12 with radiotherapy.
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Combination of Novel Gene Therapy and Immunotherapy Being Evaluated for Synergistic Anti-Tumor Activity in Patients with Cancer with Limited Treatment Options
Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and U.S. centers.
Alector, Inc., a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001.
BerGenBio ASA presents study updates from its Phase II clinical development programme with bemcentinib, a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer at the 2019 World Conference on Lung Cancer in Barcelona, Spain.
PRESS RELEASES